CREATES Act of 2017
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Apr 27, 2017)
Creating and Restoring Equal Access To Equivalent Samples Act of 2017 or the CREATES Act of 2017
This bill permits the developer of a drug or biological product to bring a civil action against the license holder of an approved drug or biological product if the holder has declined to make available sufficient quantities of the approved drug or product for the developer's testing.
What just happenedApr 28, 2017
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseApr 27, 2017
- Apr 28, 2017Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Apr 27, 2017IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Judiciary Committee - Apr 27, 2017IntroReferralH11100-A
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Apr 27, 2017IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Apr 27, 2017IntroReferralIntro-H
Introduced in House
- Apr 27, 2017IntroReferral1000
Introduced in House